Benjamin Clayton, assistant professor of genetics and genome sciences at Case Western Reserve University School of Medicine, was recognized as a recipient of the End Alexander Disease Foundation’s (End AxD) inaugural 2025 Grant Program.
Grants typically range from $50,000 to $100,000 in direct costs for up to two years and focuses on:
- Advancing the therapeutic pipeline;
- Deepening an understanding of fundamental disease mechanisms; and
- Building high-value, long-term tools that will empower the wider research community to accelerate discoveries that will lead to potential treatments.
“Dr. Clayton brings a fresh, glia-focused methodology and a rigorous translational focus to the enormous unmet need in Alexander Disease,” said Thomas Wagner, End AxD board member. “We are hopeful that the application of his pioneering phenotypic screening platform and deep molecular characterization of AxD astrocytes will not only sharpen the entire field’s understanding of disease processes but also identify specific drug candidates with the potential to transform patient outcomes.”
